Consequently, several HDAC-targeting agents have been approved for cancer treatment: to date, 4 HDAC inhibitors are U.S. Food & Drug Administration (FDA) approved: SAHA, romidepsin, belinostat, and panobinostat4. Here, HDAC9 is linked to cancer.